Hyderabad: Divi’s Laboratories Ltd., one of India’s leading pharmaceutical and active pharmaceutical ingredient (API) manufacturers, delivered an outstanding performance in the first quarter of FY27. The company reported robust double-digit growth in revenue, operating profit, and net profit, with EBITDA margin expanding sharply compared to the same period last year.
The strong quarterly performance reflects healthy demand across key business segments, improved operating leverage, and a favourable product mix.
Divi’s Laboratories Q1 FY27 Financial Highlights
Divi’s Laboratories reported consolidated net profit of ₹902 crore for Q1 FY27, compared with ₹545 crore in the corresponding quarter last year. This represents an impressive 65.5% year-on-year increase, making it one of the company’s strongest quarterly earnings performances in recent years.
The company also posted strong top-line growth. Revenue from operations increased to ₹3,080 crore, up from ₹2,400 crore in Q1 FY26, registering a 28.3% year-on-year growth.
Operating performance improved even more sharply. EBITDA surged to ₹1,255 crore, compared with ₹730 crore in the year-ago quarter, reflecting a remarkable 71.9% year-on-year increase.
Divi’s Laboratories EBITDA Margin Expands to 40.75%
One of the biggest highlights of the quarter was the sharp improvement in operating profitability.
EBITDA margin increased to 40.75%, compared with 30.25% in Q1 FY26—an expansion of 10.5 percentage points.
The significant margin improvement indicates that Divi’s Laboratories benefited from better product mix, higher capacity utilisation, and improved operating efficiency. Margin expansion of this magnitude is particularly noteworthy in the pharmaceutical manufacturing industry, where input costs and pricing pressures often impact profitability.
Divi’s LaboratoriesStrong Demand Drives Earnings Growth
The company’s strong financial performance reflects continued demand across its API and custom synthesis businesses.
Divi’s Laboratories has built a strong global presence by supplying pharmaceutical ingredients to major international drug manufacturers. Its diversified portfolio and long-term customer relationships have helped the company maintain consistent growth despite changing market conditions.
The sharp rise in revenue combined with a substantial improvement in margins demonstrates the company’s ability to convert higher sales into significantly stronger operating profits.
Divi’s Laboratories Positive Outlook for FY27
The impressive Q1 results provide a strong start to FY27 and reinforce confidence in Divi’s long-term growth strategy.
Investors will closely monitor:
– Demand for APIs and custom synthesis services.
– New product launches and customer additions.
– Capacity expansion and utilisation levels.
– Sustainability of EBITDA margins.
– Export demand and regulatory developments.
With the global pharmaceutical industry continuing to diversify supply chains, Indian API manufacturers such as Divi’s Laboratories remain well positioned to benefit from long-term growth opportunities.
Conclusion
Divi’s Laboratories delivered an exceptional Q1 FY27 performance, with net profit surging 65.5%, revenue growing 28.3%, and EBITDA jumping nearly 72% year-on-year.
The standout feature of the quarter was the EBITDA margin expanding to 40.75% from 30.25%, highlighting a significant improvement in operational efficiency and profitability.
Overall, the results reinforce Divi’s Laboratories’ position as one of India’s strongest pharmaceutical manufacturers, with solid earnings momentum and a favourable outlook for the remainder of FY27.
Also see